Abstract. HCLS1-associated protein X-1 (HAX-1) is highly expressed or overexpressed in various types of human tumor, and its overexpression is associated with cancer metastasis and cellular proliferation. However, the precise molecular mechanism involved in HAX-1-associated proliferation and metastasis in hypopharyngeal carcinoma is unknown. The present study aimed to investigate the role of HAX-1 in the metastasis and proliferation of hypopharyngeal carcinoma. Reverse transcription-quantitative polymerase chain reaction analysis and western blotting indicated that HAX-1 was overexpressed in hypopharyngeal carcinoma specimens. MTT, clone formation and transwell assays were performed to detect the effects of HAX-1 knockdown or overexpression on the major oncogenic properties of the FaDu hypopharyngeal carcinoma cell line. Downregulation of HAX-1 was observed to significantly suppress cellular proliferation, migration and clonal. By contrast, overexpression of HAX-1 significantly promoted cellular proliferation, migration and clonal formation. Furthermore, HAX-1 knockdown markedly suppressed epithelial-mesenchymal transition. In conclusion, HAX-1 is a potential oncogene, and may promote the tumorigenesis and progression of hypopharyngeal carcinoma, as well as serve as a valuable molecular target for the treatment of hypopharyngeal carcinoma.
Introduction
As a type of head and neck squamous cell carcinoma, hypopharyngeal carcinoma has a poor prognosis and an incidence of ~10 cases/million people every year (1) , and its overall survival rate is 15-45% (2) . Although the locoregional control of the cancer has been significantly improved in previous decades due to the advent of various novel treatments, including surgery, radiotherapy and chemotherapy, there has been no significant improvement in the survival rates of patients with hypopharyngeal carcinoma. Therefore, developing novel prognostic markers to facilitate patient management is of the utmost importance.
HCLS1-associated protein X-1 (HAX-1) is a family of ubiquitously expressed proteins ranging between 26 and 35 kDa in size, which result from alternative splicing of the single HAX-1 gene (3). The human HAX-1 gene is located on chromosome 1 (1q21.3) (4). HAX-1 is involved in a variety of important physiological processes, including the regulation of apoptosis, cell motility and endocytosis, and combination with the 3' untranslated regions (5) (6) (7) (8) . Accumulating evidence has also proved that HAX-1 is highly expressed or overexpressed in various types of human tumor, including colorectal cancer (9) , esophageal squamous carcinoma (10) , oral squamous cell carcinoma (11) , hepatocellular carcinoma (12) , breast cancer, lung cancer (13) , B lymphoma (14) and melanoma (15) . In addition, HAX is associated with the pathogenesis of malignancies and other diseases, including psoriasis and systemic sclerosis (5) . However, the expression pattern and possible roles of HAX-1 in hypopharyngeal carcinoma have not been investigated.
In the present study, the role of HAX-1 in the processes of cellular proliferation and tumorigenesis in hypopharyngeal carcinoma was investigated. HAX-1 was observed to be overexpressed in hypopharyngeal carcinoma tissues and cell lines. It was also observed that HAX-1 regulates the growth, proliferation and migration of the FaDu hypopharyngeal carcinoma cell line.
Materials and methods
Tissue samples and cell culture. A total of 24 pairs of primary hypopharyngeal squamous cell carcinoma and corresponding non-malignant tissue specimens were obtained from patients Small-interfering RNA (siRNA) transfection. For the siRNA silencing of HAX-1, RNA interference was performed using synthetic siRNA. HAX-1 siRNA and scrambled siRNA were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China). HAX-1 siRNA1, 5'-CCA CGA TAA CTT CGG CTT T-3'; siRNA2, 5'-GCC ATT TCA TAG GTT TGA T-3'; and siRNA3, 5'-GGA CTC AAT GCT TAA GTA T-3' and scram bled siRNA, 5'-GCA GAT AGG TAG GCG TTA T-3'. HAX-1 siRNAs or scramble siRNA were transfected into FaDu cells using Lipofectamine RNAiMAX transfection reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. A total of 24 h prior to transfection, FaDu cells were plated in 6-well plates at a density of 2x10 4 cells/well in antibiotic-free culture medium. The following day, 3 µl Lipofectamine RNAiMax transfection reagent was combined with 120 pmol siRNA (6 µl from a 20 µM stock) in a volume of 250 µl Opti-MEM medium (Gibco; Thermo Fisher Scientific, Inc.) and incubated for 20 min; the complexes of Lipofectamine RNAiMax and siRNAs were then added directly to each well. After 24 h of transfection at 37˚C in a humidified atmosphere containing 5% CO 2 , cells were harvested for cellular proliferation, migration and colony formation assays.
Plasmid construction and transfection. HAX-1 overexpression vector was constructed using the polymerase chain reaction (PCR) method. Briefly, constructs contai ning human HAX-1-GFP fusions were generated by cloning the cDNA of the HAX1 coding region into a pEGFP-N1 vector (Clontech Laboratories, Inc., Mountainview, CA, USA). The HAX-1 cDNA was isolated from healthy human embryonic kidney 293 cells and the coding sequence was obtained using the following specific primers: Forward, 5'-GGA ATT CGG GAA TGA GCC TCT TTG-3', containing an EcoRI restriction site; and reverse, 5'-CGG GAT CCC GCC GGG ACC GGA AC-3', containing a BamHI restriction site. PCR was then conducted using a thermal cycler (MJ Research, Inc., Waltham, MA, USA), under the following conditions: A total of 30 cycles of denaturation at 94˚C for 30 sec, annealing at 56˚C for 30 sec and extension at 72˚C for 70 sec. The PCR products were confirmed by direct DNA sequencing and cloned into the mammalian expression vector pEGFP-N1. FaDu cells were used for the overexpression studies. Stably-transfected clones were obtained by G418 selection (Promega Corporation, Madison, WI, USA). A stable transfectant of the pEGFP-N1 empty vector was used as a control. For transfection, complexes of Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) and plasmid were prepared according to the manufacturer's protocol, and these complexes were directly mixed with cells in 24-well cell culture plates at a density of 4x10 4 cells/well. The level of HAX-1 expression following transfection was assayed by western blot analysis.
Reverse transcription-quantitative PCR (RT-qPCR).
TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from the cells and tissue specimens. First-strand cDNA was synthesized from 1 µg total RNA using High Capacity cDNA Reverse Transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.). qPCR was performed in a total volume of 20 µl using SYBR-Green PCR Master mix (Roche Diagnostic GmbH, Mannheim, Germany) on a 7900HT Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Thermocycling conditions were as follows: Initial denaturation at 95˚C for 10 min, followed by 40 cycles of denaturation at 95˚C for 15 sec and annealing/extension at 63˚C for 60 sec. All reactions were performed in duplicate. The mRNA expression levels of HAX-1 were normalized to GAPDH mRNA levels using the 2 -ΔΔCq method (16) . The PCR primers were synthesized by Invitrogen (Thermo Fisher Scientific, Inc.) and the sequences were as follows: HAX-1 forward, 5'-CCC AAC CAG CAC CAG ACT-3' and reverse, 5'-GCT CCT CCA CTA TCC CAT CT-3'; and GAP DH forward, 5'-CGG ATT TGG TCG TAT TGG G-3' and reverse, 5'-CGC TCC TGG AAG ATG GTG AT-3'.
Western blotting. Total protein was extracted using lysis buffer containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Igepal, 0.1% SDS, 0.25% sodium deoxycholate, 1 mM EDTA pH 7.4 and protease inhibitors (Promega Corporation) on ice for 1 h. Total protein concentration was determined using a bicinchoninic acid protein assay (Pierce; Thermo Fisher Scientific, Inc.). Equal amounts of extracted protein samples (20 µg) were separated by 12% SDS-PAGE and transferred onto a nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Following blocking in 5% non-fat milk for 1 h at room temperature, the membrane was incubated with the following primary antibodies at 4˚C overnight: Anti-HAX-1 (1:500; cat. no. sc-28268; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-E-cadherin (1:1,000; cat. no. ab1416; Abcam, Cambridge, MA, USA), anti-vimentin (1:1,000; cat. no. ab92547; Abcam), anti-N-cadherin (1:500; cat. no. ab18203; Abcam) and anti-β-actin (1:2,000; cat. no. A1978; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The membrane was washed thrice with TBS containing 0.1% Tween-20 and then incubated with the following horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature: Goat anti-mouse immunoglobulin (Ig) G (1:10,000; cat. no. 31430; Thermo Fisher Scientific, Inc.) and goat anti-rabbit IgG (1:10,000; cat. no. 31460; Thermo Fisher Scientific, Inc). The protein bands were detected using enhanced chemiluminescence (GE Healthcare Life Sciences, Little Chalfont, UK) and blots were semi-quantified using ImageJ software version 1.41 (National Institutes of Health, Bethesda, MD, USA).
MTT assay. After 1, 2, 3, 4 and 5 days of transfection, FaDu cells were digested, diluted to a density of 3x10 4 cells/ml and plated in 96-well plates (100 µl cell suspension/well). The cells were cultured at 37˚C for 24 h, and cell proliferation was evaluated using an MTT assay (Sigma-Aldrich; Merck KGaA), according to the manufacturer's protocol. A total of 10 µl (5 mg/ml) MTT solution was added to the culture medium, and cells were incubated for an additional 4 h. The formazan precipitates were dissolved in 200 µl dimethyl sulfoxide (Sigma-Aldrich; Merck KGaA). The absorbance of each sample was determined at a wavelength of 490 nm using a microplate reader (BioTek Instruments, Inc., Winooski, VT, USA).
Colony formation assay. For the colony formation assay, a total of 800 cells were plated in complete growth media and allowed to grow until visible colonies formed (14 days). Cells in the plates were fixed with 100% methanol for 10 min at room temperature and stained with 0.5% crystal violet for 20 min at room temperature, and the number of colonies (>50 cells) was counted under an optical microscope. The experiment was performed in triplicate and repeated three times. 8-µm pore size). Cells were incubated in medium without serum and medium with 10% fetal bovine serum served as a chemoattractant in the lower chambers. After 24 h of incubation at 37˚C in a humidified atmosphere containing 5% CO 2 , cells that did not migrate through the pores were carefully wiped out with cotton wool. Cells on the lower membrane were fixed with 100% methanol for 10 min and stained with 0.2% crystal violet for 20 min at room temperature. Images of the inserts were captured and migrated cells were counted in 5 randomly selected fields under an inverted microscope (Olympus Corporation, Tokyo, Japan).
Statistical analysis. Statistical calculations were performed using the SPSS software package (version 17.0; SPSS, Inc., Chicago, IL, USA). The Student's t-test was used to evaluate the differences between two groups. One-way analysis of variance was used to analyze the comparison of means in more than two groups. Data are presented as the mean ± standard error of the mean. P<0.05 was considered to indicate a statistically significant difference.
Results

HAX-1 overexpression in hypopharyngeal carcinoma.
To investigate whether HAX-1 is expressed in hypopharyngeal carcinoma, western blot analysis was used to analyze the 24 hypopharyngeal carcinoma tissues and matched non-tumor hypopharyngeal epithelial samples (Fig. 1A) . The mean HAX-1 protein level in hypopharyngeal carcinoma tissues was demonstrated to be significantly increased compared with in the adjacent non-tumor tissues (P=0.004; Fig. 1B) . Furthermore, RT-qPCR analysis was performed in the 24 tumor tissues and the corresponding non-tumor samples. The results demonstrated that the expression of HAX-1 was significantly increased in hypopharyngeal carcinoma samples 
Downregulation of HA X-1 suppressed viability and prolif eration in FaDu cells in vitro.
Western blot analysis demonstrated that HAX-1 siRNA1 decreased the level of HAX-1 expression more effectively than scramble and other siRNAs ( Fig. 2A) . To measure the effect of HAX-1 downregulation on the viability and proliferative ability of FaDu cells in vitro, MTT and colony formation assays were performed. The MTT assay demonstrated that HAX-1 siRNA1 significantly inhibited the viability of the FaDu cells compared with the scrambled siRNA ( Fig. 2B; P<0 .05). As presented in Fig. 2C , the colony formation assay demonstrated the plate colony number in the HAX-1 siRNA1 group was decreased compared with the scrambled siRNA group (P<0.05). These results indicated that the downregula tion of HAX-1 expression inhibited the viability and proliferative ability of FaDu cells.
Downregulation of HAX-1 inhibited the migratory potential of FaDu cells in vitro.
To investigate the effect of HAX-1 downregulation on the migratory potential of FaDu cells, transwell assays were performed. The results demonstrated that the number of migratory cells in the HAX-1 siRNA1 treatment group was significantly decreased compared with the scramble siRNA treatment group ( Fig. 2D; P<0 .05). These results revealed that downregulation of HAX-1 expression suppressed the migratory ability of FaDu cells.
Overexpression of HAX-1 promoted the viability, proliferation and migration of FaDu cells in vitro.
Western blot analysis demonstrated that endogenous HAX-1 expression was significantly increased in the HAX-1 overexpression vector group compared with the control vector group (Fig. 3A) . The effects of HAX-1 on cell viability and proliferation were analyzed by MTT and colony formation assays, respectively, and the results indicated that upregulation of HAX-1 expression enhanced the (Fig. 3B and C, respectively; P<0.05). In addition, overexpression of HAX-1 significantly increased the number of migratory FaDu cells by transwell assay (Fig. 3D; P<0.05) .
Downregulation of HAX-1 suppressed epithelial-mesenchymal transition (EMT).
EMT has recently been linked to tumor progression, through which epithelial cells acquire mesenchymal properties, and exhibit reduced intercellular adhesion and increased motility (17) . Through western blot analysis, downregulation of HAX-1 was observed to inhibit the protein expression of epithelial (E)-cadherin, and induce the protein expression of vimentin and neural (N)-cadherin, compared with the scramble siRNA group ( Fig. 4A and B; P<0.05) . Whereas, in the HAX-1 overexpression cells, vimentin and N-cadherin expression was upregulated, and E-cadherin expression was downregulated ( Fig. 4C and D; P<0.05).
Discussion
HAX-1 is ubiquitously expressed in human and murine tissues, and is reported to be localized to the mitochondria, nuclear membrane and endoplasmic reticulum (11) . HAX-1 is characterized by the activation and permeabilization of mitochondria, resulting in the release of cytochrome c and other proapoptotic molecules into the cytosol (18) . A previous study demonstrated that HAX-1 comprises a family of apoptotic regulators with antagonistic roles in response to oxidative stress (19) . Previously, a study confirmed that HAX-1 expression is a predictor of tumorigenesis, growth, progression, invasion and metastasis in multiple human malignancies, and is increased in numerous types of tumor (11) . In the present study, using RT-qPCR and western blot analysis, HAX-1 expression was observed to be increased in hypopharyngeal carcinoma tissues.
A previous study reported that there was HAX-1 overexpression in esophageal squamous cell carcinoma samples, and that the level of HAX-1 mRNA is a risk factor for lymph node metastasis and indicator of survival in patients with esophageal squamous cell carcinoma (10) . Another study suggested that HAX-1 expression was elevated in hepatocellular carcinoma samples, and that high expression of HAX-1 was associated with histological grade, tumor size, cirrhosis and poor clinical outcome (12) . Furthermore, high HAX-1 expression in breast cancer is associated with poor prognosis (20) . It has also been demonstrated that upregulated HAX-1 is associated with advanced clinicopathological characteristics and prognosis in colorectal cancer (9) . A previous study reported on HAX-1-mediated chemotherapeutic resistance in T-cell leukemia and melanoma (21) . Furthermore, previous results suggested a critical scaffolding role for HAX-1 in lysophosphatidic acid-stimulated Ras-related C3 botulinum toxin substrate 1-cortactin interaction and subsequent ovarian cancer cell migration (22) . It has also been demonstrated that reduction of HAX-1 levels by siRNA suppresses α v β 6 -dependent carcinoma cell migration by downregulating α v β 6 endocytosis via a clathrin-mediated pathway (11) . The present study demonstrated that downregulation of HAX-1 in FaDu cells significantly inhibits cell viability, proliferation and migration in vitro. Furthermore, downregulation of HAX-1 expression resulted in the increase of epithelial marker E-cadherin, and the decrease of mesenchymal markers vimentin and N-cadherin. The results of the present study were corroborated by previous findings where HAX-1 is overexpressed in a number of cancer types and exhibits a number of oncogenic functions.
In conclusion, to the best of the author's knowledge, the results of the present study demonstrated for the first time that HAX-1 is overexpressed in hypopharyngeal carcinoma. Furthermore, knockdown of HAX-1 may inhibit the viability, proliferative and migratory abilities of FaDu cells in vitro. These results provide important information for the identification and characterization of a novel molecular marker, and a target for hypopharyngeal carcinoma therapy. 
